|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Current assets | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Short-term investments | |||||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Long-term investments | |||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||||
| Restricted cash | |||||||||||||||||||
| Other noncurrent assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| Liabilities and stockholders' equity | |||||||||||||||||||
| Current liabilities | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||||||
| Total accrued expenses and other liabilities | |||||||||||||||||||
| Current portion of operating lease liabilities | |||||||||||||||||||
| Current portion of deferred revenue | |||||||||||||||||||
| Current portion of other liabilities | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Noncurrent operating lease liabilities | |||||||||||||||||||
| Deferred revenue, net of current portion | |||||||||||||||||||
| Other noncurrent liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Stockholders’ equity: | |||||||||||||||||||
| Preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued and outstanding. | |||||||||||||||||||
| Common stock, $0.001 par value, 200,000 shares authorized as of March 31, 2025 and December 31, 2024; 60,969 and 60,456 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Accumulated other comprehensive income | |||||||||||||||||||
| Total stockholders' equity | |||||||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||||||
| Preferred stock, par value (in dollars per share) | |||||||||||||||||||
| Preferred stock, shares authorized (in shares) | |||||||||||||||||||
Loading...
